Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Abarelix, Praecis pharmaceuticals.

C Doehn1, D Jocham

  • 1Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. doehn@medinf.mu-luebeck.de

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary

Abarelix, an LHRH receptor antagonist, is in late-stage clinical trials for prostate cancer and endometriosis. Pharmaceutical companies are developing this drug for hormone-related disorders, with projected European launch in 2001.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
Same author

[Update of the German S3 guideline on renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

Der Urologe. Ausg. A·2021
Same author

[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]

Der Urologe. Ausg. A·2020
Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Abarelix is a luteinizing hormone-releasing hormone (LHRH) receptor antagonist.
  • It is under development for prostate cancer, breast cancer, and other hormone-related disorders.

Purpose of the Study:

  • To summarize the development status and market projections for Abarelix.

Main Methods:

  • Review of clinical trial phases and collaboration agreements.
  • Analysis of market sales predictions from financial institutions.

Main Results:

  • Abarelix is in Phase III trials for prostate cancer and Phase I/II for endometriosis.
  • Multiple pharmaceutical collaborations and licensing agreements have been established.
  • Projected European launch in 2001 with significant sales forecasts.

Related Experiment Videos

Conclusions:

  • Abarelix is a promising LHRH antagonist with advanced clinical development.
  • Strategic partnerships are in place for its global development and marketing.